| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 78,883 | - | ||
| General and administrative | 11,353 | - | ||
| Total operating expenses | 90,236 | - | ||
| Loss from operations | -90,236 | -80,873 | ||
| Interest expense | 1,092 | 1,172 | ||
| Loss on extinguishment of loan payable | -1,557 | - | ||
| Interest and other income, net | 11,319 | 11,540 | ||
| Net loss | -81,566 | -70,505 | ||
| Net unrealized gain on marketable securities | 838 | -97 | ||
| Comprehensive loss | -80,728 | -70,602 | ||
| Net loss per share, basic | -0.99 | -0.86 | ||
| Net loss per share, diluted | -0.99 | -0.86 | ||
| Weighted-average number of shares used in computing net loss per common share, basic | 82,008,267 | 81,721,387 | ||
| Weighted-average number of shares used in computing net loss per common share, diluted | 82,008,267 | 81,721,387 | ||
Akero Therapeutics, Inc. (AKRO)
Akero Therapeutics, Inc. (AKRO)